NAS:AXSM (USA) Also trade in: Germany UK

Axsome Therapeutics Inc

$ 23.47 -0.7 (-2.9%)
Volume: 903,553 Avg Vol (1m): 1,288,063
Market Cap $: 781.67 Mil Enterprise Value $: 758.40 Mil
P/E (TTM): 0.00 P/B: 44.62
Earnings Power Value 0.69
Net Current Asset Value 0.52
Tangible Book 0.53
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.20
Cash-To-Debt ranked higher than
56.49% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
AXSM: 2.2
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.56, Med: 3.28, Max: 10000
Current: 2.2
0.56
10000
Debt-to-Equity 1.11
Debt-to-Equity ranked lower than
77.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
AXSM: 1.11
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -1.86, Med: 0.59, Max: 10.4
Current: 1.11
-1.86
10.4
Debt-to-EBITDA -0.54
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
AXSM: -0.54
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -2.05, Med: -0.36, Max: -0.23
Current: -0.54
-2.05
-0.23
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 12.74
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 21.37%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -476.07
ROE ranked lower than
100.00% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
AXSM: -476.07
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -476.07, Med: -115.59, Max: -56.48
Current: -476.07
-476.07
-56.48
ROA % -147.12
ROA ranked lower than
81.00% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
AXSM: -147.12
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -245.79, Med: -90.91, Max: -47.09
Current: -147.12
-245.79
-47.09
ROC (Joel Greenblatt) % -60420.61
ROC (Joel Greenblatt) ranked lower than
92.37% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
AXSM: -60420.61
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -135000, Med: -47804.83, Max: -32666.27
Current: -60420.61
-135000
-32666.27
3-Year Total EBITDA Growth Rate -37.50
3-Year EBITDA Growth Rate ranked lower than
83.92% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
AXSM: -4.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -113.5, Med: -39.5, Max: -4.9
Current: -4.9
-113.5
-4.9
3-Year EPS w/o NRI Growth Rate -4.10
3-Year EPS w/o NRI Growth Rate ranked lower than
82.83% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
AXSM: -4.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -29.1, Max: -4.1
Current: -4.1
0
-4.1

» AXSM's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AXSM

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XMCE:IKM LSE:OPTI TSX:COM NAS:INNT ASX:CPH XCNQ:MMJ LSE:DEST WBO:MSBT TPE:1762 OSTO:CANTA TSX:HBP HKSE:03839 NAS:APVO OHEL:BIOBV XPAR:ALTHX ROCO:3205 NAS:SPHS ROCO:4192 AMEX:NAVB AMEX:NBY
Traded in other countries 19X.Germany 0HKF.UK
Address 25 Broadway, 9th Floor, New York, NY, USA, 10004
Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.

Ratios

Current vs industry vs history
PB Ratio 44.62
PB Ratio ranked lower than
100.00% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
AXSM: 44.62
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 700.3
Current: 44.62
0
700.3
EV-to-EBIT -21.19
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
AXSM: -21.19
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -25.89, Med: 0, Max: 0
Current: -21.19
-25.89
0
EV-to-EBITDA -21.22
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
AXSM: -21.22
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -25.92, Med: 0, Max: 0
Current: -21.22
-25.92
0
Current Ratio 5.68
Current Ratio ranked lower than
64.25% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
AXSM: 5.68
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.51, Med: 4.11, Max: 18.63
Current: 5.68
0.51
18.63
Quick Ratio 5.68
Quick Ratio ranked lower than
61.08% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
AXSM: 5.68
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.51, Med: 4.11, Max: 18.63
Current: 5.68
0.51
18.63

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.00
3-Year Share Buyback Rate ranked lower than
69.54% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
AXSM: -12
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -26, Med: -14.6, Max: -12
Current: -12
-26
-12

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 44.28
Price-to-Tangible-Book ranked lower than
100.00% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
AXSM: 44.28
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.56, Med: 5.85, Max: 123.21
Current: 44.28
2.56
123.21
Earnings Yield (Joel Greenblatt) % -4.73
Earnings Yield (Greenblatt) ranked lower than
86.40% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
AXSM: -4.73
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -666.7, Med: 0, Max: 0
Current: -4.73
-666.7
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N